Skip to main content

This job has expired

You will need to login before you can apply for a job.

VP, Pharmacology & Toxicology

Employer
AnaptysBio, Inc.
Location
San Diego, CA, US
Start date
May 23, 2020

View more

Discipline
Science/R&D, Pharmacology, Toxicology
Required Education
Doctorate/PHD/MD
Position Type
Full time
Hotbed
Biotech Beach

Job Details

We are seeking a head of Pharmacology/Toxicology to lead a team in executing early clinical drug development activities evaluating the pharmacology and toxicology of antibody therapeutics focused primarily, but not exclusively, on immune-inflammatory diseases. As a key member of the development team, this role liaises with Discovery Project Team Leaders. The VP, Pharmacology & Toxicology serve as a Development project team leader, where appropriate, and work collaboratively with the executive management to develop strategies for key programs, and strengthen the capabilities of the company.

This position reports to the Chief Medical Officer.

Some responsibilities include:
  • Crafting the pre-clinical and clinical pharmacological strategies, including dose escalation, contributing to stopping rules, and risk-benefit to ascertain that compounds are entered into man safely, efficiently and with scientific validity.
  • Overseeing the development and validation of quantitative in vivo assays to enable pharmacological characterization of therapeutic antibodies
  • Establishing collaboration with CROs and/or academic institutions to develop in vivo pharmacology models to permit progression into the clinic of therapeutic antibodies
  • Providing strategic and tactical direction to multiple project teams
  • Preparing study reports for regulatory submission on development candidates
  • Contributing to new project ideas and in vivo proof-of-concept studies to enable the initiation of new antibody projects
  • Leading the Development project team and oversee the transition from discovery to clinical development of new antibodies


Requirements

Education & Experience
  • PhD in Pharmacology or related science with a minimum of 15 years' experience in a drug-discovery setting of a biopharmaceutical company, accompanied by at least 5 years of proven leadership experience.
  • Extensive experience in developing quantitative in vivo pharmacodynamic assays and preclinical disease models to assess target engagement and efficacy in a range of inflammatory/autoimmune conditions
  • Proven track record of making major contributions to the discovery of one or more marketed or in-development medicines
  • Prior experience of working across diverse therapeutic areas is highly desirable
  • Sound theoretical and experimental background in biology coupled with a solid foundation in quantitative pharmacology


Skills & Knowledge
  • Expert knowledge of pharmacokinetics, toxicology, and formulation
  • Ability to perform randomized controlled clinical trial principles, methodology and procedures
  • Skilled at statistical data collection, editing, validation and analysis techniques
  • Proven managerial competence with previous experience in directly managing teams

Company

AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our PD-1 agonist program in a Phase 2 trial for the treatment of moderate-to-severe rheumatoid arthritis; and ANB032, our BTLA agonist program, currently in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis. Our preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody for the treatment of autoimmune and inflammatory diseases. In addition, AnaptysBio has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready. AnaptysBio has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immune-oncology, including an anti-PD-1 antagonist antibody (Jemperli (dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).

Our corporate vision is to transform patient health by delivering innovative immunology therapeutics. Find out more about us by following us on Twitter.

 

CONNECT

Twitter  

Company info
Website
Phone
858-362-6295
Location
10770 Wateridge Circle
Suite 210
San Diego
California
92121
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert